Helicobacter pylori (H. pylori)-related chronic atrophic gastritis (CAG) is a condition where long-term infection by H.
Helicobacter pylori (H. pylori)-related chronic atrophic gastritis (CAG) is a condition where long-term infection by H. pylori bacteria leads to damage in the stomach lining. This damage includes inflammation, loss of stomach gland cells (atrophy), and replacement of normal stomach tissue with intestinal-like cells, known as intestinal metaplasia (IM). CAG caused by H. pylori significantly increases the risk of developing gastric cancer.
H. pylori is classified as a Class I carcinogen due to its strong link to stomach cancer. The bacteria release harmful proteins, such as CagA and VacA, which disrupt normal cell functions, trigger chronic inflammation, and cause DNA damage. This persistent inflammation accelerates the progression of Correa’s cascade, a step-by-step process from gastritis to IM, dysplasia (abnormal cell growth), and eventually gastric cancer. Additionally, H. pylori can evade the immune system, allowing the infection to persist and promote cancer development.
Epigenetic changes, such as DNA methylation, play a major role in this process. H. pylori silences tumor-suppressor genes and activates cancer-promoting pathways like WNT and NF-κB. Co-infection with Epstein–Barr virus (EBV) further increases cancer risk through combined effects on cellular growth and signaling.
While early eradication of H. pylori can prevent progression, advanced stages of IM or dysplasia may become irreversible. Treatment typically involves antibiotics combined with proton pump inhibitors, with newer therapies like vonoprazan showing promise. Regular monitoring after eradication is essential, as early detection and intervention can significantly reduce the risk of gastric cancer.
Introduction: Barrett's esophagus (BE) is the principal precursor of esophageal adenocarcinoma. Early detection of neoplastic transformation is essential for preventing cancer progression. This review discusses basal crypt dysplasia (CD), an emerging histological entity that may...
Introduction: Assessing esophageal clearance after peroral endoscopic myotomy (POEM) is essential for evaluating treatment success in achalasia. Timed barium esophagram (TBE) is the current standard, but high-resolution impedance manometry (HRiM) may provide a radiation-free physiological...
Introduction: Magnetic sphincter augmentation (MSA) has emerged as an effective surgical option for patients with gastroesophageal reflux disease (GERD) who continue to experience symptoms despite medical therapy. By augmenting lower esophageal sphincter function while preserving...
Introduction: Helicobacter pylori infection affects more than half of the global population and remains a major cause of peptic ulcer disease, gastric mucosal inflammation, and gastric cancer. Successful eradication is a cornerstone of gastrointestinal practice,...
Introduction: Helicobacter pylori Infection eradication after prior treatment failure remains a major therapeutic challenge due to increasing antibiotic resistance, poor tolerability of multidrug regimens and declining adherence rates. Simplified rescue strategies with improved safety and...
Introduction Helicobacter pylori Infection eradication is widely accepted as a key strategy for prevention of Gastric Cancer. Large meta-analyses have consistently shown reductions in gastric cancer incidence following eradication therapy, supporting global screening and treatment...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.